BACKGROUND/AIMS: Early gastric cancer (EGC) can be treated by endoscopic resection, which results in an excellent prognosis. Optimal screening intervals considering risk factors for gastric cancer have not been established. The aim of this study was to determine the maximum gastric cancer screening interval in terms of long-term survival. METHODS: Curative resection was performed in 561 patients with gastric cancer who had completed a questionnaire on their previous history of screening tests and risk factors. The association between EGC detection rate and previous screening history was evaluated, and 5-year disease-free survival rates were compared between various screening intervals. RESULTS: Multivariate analysis showed that intestinal metaplasia [hazard ratio (HR) 9.690, 95% confidence interval (CI) 5.896-15.927] and previous screening history (HR 0.077, 95% CI 0.048-0.125) were independent factors associated with advanced gastric cancer. In patients without intestinal metaplasia, there was no significant difference in the extent of gastric cancer progression and the 5-year disease-free survival rate between groups with screening intervals of less than 3 years. In patients with intestinal metaplasia, the cutoff screening interval for detection of EGC and disease-free survival was 2 years. CONCLUSION: The optimum screening interval for disease-free survival for gastric cancer in a normal population is 3 years, but a screening interval of 2 years should be used for patients with intestinal metaplasia in Korea.
BACKGROUND/AIMS: Early gastric cancer (EGC) can be treated by endoscopic resection, which results in an excellent prognosis. Optimal screening intervals considering risk factors for gastric cancer have not been established. The aim of this study was to determine the maximum gastric cancer screening interval in terms of long-term survival. METHODS: Curative resection was performed in 561 patients with gastric cancer who had completed a questionnaire on their previous history of screening tests and risk factors. The association between EGC detection rate and previous screening history was evaluated, and 5-year disease-free survival rates were compared between various screening intervals. RESULTS: Multivariate analysis showed that intestinal metaplasia [hazard ratio (HR) 9.690, 95% confidence interval (CI) 5.896-15.927] and previous screening history (HR 0.077, 95% CI 0.048-0.125) were independent factors associated with advanced gastric cancer. In patients without intestinal metaplasia, there was no significant difference in the extent of gastric cancer progression and the 5-year disease-free survival rate between groups with screening intervals of less than 3 years. In patients with intestinal metaplasia, the cutoff screening interval for detection of EGC and disease-free survival was 2 years. CONCLUSION: The optimum screening interval for disease-free survival for gastric cancer in a normal population is 3 years, but a screening interval of 2 years should be used for patients with intestinal metaplasia in Korea.
Authors: Sun Jin; Seong Woo Jeon; Yonghwan Kwon; Su Youn Nam; Seong Jae Yeo; Sang Hoon Kwon; Sang Jik Lee Journal: J Korean Med Sci Date: 2018-05-09 Impact factor: 2.153
Authors: Mi Sung Park; Ji Young Yoon; Hyun Soo Chung; Hyuk Lee; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee Journal: Gut Liver Date: 2015-03 Impact factor: 4.519
Authors: Jieun Kim; Su Mi Kim; Man Ho Ha; Jeong Eun Seo; Min-Gew Choi; Jun Ho Lee; Tae Sung Sohn; Sung Kim; Sin-Ho Jung; Jae Moon Bae Journal: Medicine (Baltimore) Date: 2016-12 Impact factor: 1.817